Astrazeneca plc - ADR

Astrazeneca plc - ADR

AZN

Get informed when a big investor buys or sells

+ Follow
Market Cap$294.4B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Astrazeneca plc - ADRAstrazeneca plc - ADR25.31.87%21%2.30.6

Earnings Call Q2 2026

July 27, 2026 - AI Summary

Strong H1 momentum + upgraded confidence in 2030 ambition (good) - Total revenue +6% in H1 2026 (core underlying strength highlighted as +11% excluding Farxiga & Brilinta generics). - Core EPS +11% in H1, in line with full-year guidance. - Oncology + Rare Disease delivered double-digit growth, while Respiratory/Immunology helped mitigate losses from CVRM (Farxiga/Brilinta) exclusivity. - Pipeline delivery is active: 6 key Phase III readouts in H1, including 3 new molecular entities (NMEs); 30 major market approvals, including first approvals for 2 NMEs (Etcamah in HR+ breast cancer; Baxfendy in hypertension). Company reiterated goal to reach 20 approved NMEs by 2030 (now at 11).
Financial outlook reiterated: mid-to-high single-digit revenue growth + low double-digit EPS growth (forecast) - Full-year guidance reiterated: total revenue expected to grow mid- to high single digits (CER) and core EPS low double digits (CER). - Gross margin: 83% core gross margin in H1; management expects lower gross margin in H2 due to seasonal demand in lower-margin products (e.g., FluMist, Beyfortus), but stable to slightly higher vs 2025 for the full year. - R&D intensity: 23% of revenue in H1, and full-year R&D expected upper end of low 20s % range (ongoing heavy pipeline investment). - CapEx: $1.5B in H1; expects ~+1/3 increase in 2026, including new ADC manufacturing capacity in Singapore.
Big “good news” oncology catalysts (opportunities) - Strong oncology growth in H1: Oncology revenue +15% to $14.1B. - Key readouts: - VOLGA (Imfinzi/Enfortumab +/− Imjudo) in muscle-invasive bladder cancer for cisplatin-ineligible: statistically significant and clinically meaningful improvements in event-free survival and overall survival; Imjudo arm shows EFS benefit with favorable OS trend. - CLARITY-Gastric01 (sone-ve / Claudin 18.2 ADC): reported overall survival benefit in 2nd-line plus gastric cancer, including patients with as low as 25% Claudin 18.2 expression; management calls it a landmark for C18.2 ADCs and for wholly owned ADC portfolio. Also reinforces confidence in CLARITY-Gastric02 (first-line strategy). - Commercial opportunities: - Tagrisso leadership remains strong; company is extending the franchise with combination trials and new in-licensing (Zegfrovy) for EGFR exon 20 insertions, signaling continued intent to lead the space.

Exclusive for Stockcircle Pro members

Sign upSign Up
$367.22

Current Fair Value

116.5% upside

Undervalued by 116.5% based on the discounted cash flow analysis.

Share Statistics

Market cap$294.40 Billion
Enterprise Value$319.39 Billion
Dividend Yield$3.16 (1.87%)
Earnings per Share$13.2
Beta0.23
Outstanding Shares775,500,000

Return

Return on Equity21.16%ROE
Return on Assets9.03%
Return on Invested Capital16.80%

Valuation & Multiples

P/E Ratio25.34P/E Ratio
PEG46.03PEG
Price to Sales2.26Price to Sales
Price to Book Ratio2.74Price to Book Ratio
Enterprise Value to Revenue5.44
Enterprise Value to EBIT22.78
Enterprise Value to Net Income31
Total Debt to Enterprise0.1
Debt to Equity0.63Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
July 27, 2026
EPS Estimate
$2.50
Average shareholder expectation
Revenue Estimate
$15.44 B
Average shareholder expectation

Next Earnings Call

Expected Date
August 4, 2026
EPS Estimate
$2.50
Average shareholder expectation
Revenue Estimate
$15.42 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.0000▼ 96.28%
Total Calls-▼ 100.00%
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %2.66%▼ 46.14%
Total Invested$7.81B▼ 94.84%
Investors Holding646▼ 716.00%

ESG Score

No data

About AstraZeneca Plc

CEO: Pascal Soriot

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respira...

Relevant Senate Committees

Finance

This is a critically important committee for AstraZeneca. It controls taxation (corporate tax rates, R&D credits), trade policy (affecting global supply chains and market access), and entitlement spending (Medicare/Medicaid drug pricing and reimbursement), all directly impacting profitability and revenue.

Appropriations

This committee allocates federal discretionary spending, directly impacting funding for biomedical research (e.g., NIH) and government healthcare programs that purchase pharmaceutical products, thereby affecting AstraZeneca's potential research collaborations and market opportunities.

Health, Education, Labor, and Pensions

This committee directly regulates the FDA (drug approval, safety, marketing) and NIH (research funding), making it central to AstraZeneca's product development, regulatory pathways, and market access. It profoundly impacts the pharmaceutical and biotech sectors.

Judiciary

This committee's oversight of antitrust laws directly impacts potential mergers and acquisitions, and its role in intellectual property protection (patents) is critical for pharmaceutical companies like AstraZeneca, which rely heavily on proprietary research and development.